This makes CD16 an attractive target for immunotherapy as the treatment with monoclonal antibodies, particularly monoclonal antibodies that target tumor-specific antigens or antigens overly expressed on tumor cells enable those cells to become tagged for clearance by CD16+ NK cells. The gene discussed is FCGR3A; the disease is neoplasm.